After being fired, I became the light of medicine

Chapter 17 Beifeng Pharmaceutical’s counterattack!
There is no mandatory requirement for clinical trial data of innovative drugs to be made public, whether in the United States or China.

the reason is simple,
The Phase II and Phase III clinical trials of each innovative drug are trials in which pharmaceutical companies have invested a lot of real money, and the data obtained are naturally regarded as the intangible assets of the pharmaceutical companies.

Furthermore,

Clinical data is of great significance for the research and development of new drugs. For example, some companies that are developing drugs with the same target can easily judge each other's research and development progress through their clinical data.

They can even use the other party's clinical data to conduct deeper research and development, quickly obtain patents for newer drugs, and thus gain a competitive advantage.

of course.

Zhang Yang had no such worries at all.

On the contrary, he really needs to publish the Phase II clinical data.

He knew very well that he was running out of funds, and if Qingshan Avatrombopag wanted to continue its Phase III clinical trials, he had to negotiate a deal with other pharmaceutical companies.

Zhang Yang’s plan was soon realized. After most of the data of "Qingshan Avatrombopag" was published on the website, it quickly attracted strong attention from the industry.

Jiangsu Province, Hengrui Medicine headquarters.

Hengrui Medicine is considered to be one of the top pharmaceutical research and development companies in China.

Compared with other domestic pharmaceutical companies that only focus on the research and development of traditional Chinese medicines and generic drugs with lower risks, Hengrui not only invests a large amount of money in innovative drugs every year, but also has achieved good results in major diseases such as tumors and cancer.

Several of its oncology drugs have been launched in the domestic market, and some are even exported overseas.

At this time, two middle-aged men were discussing in the president's office on the 17th floor of Hengrui's headquarters building.

"Wen Ping, two people, one is a second-level drug researcher and the other is an ordinary manager, can develop 'Avatrombopag'? Do you believe it?"

The speaker was Su Lin, President of Hengrui.

As a person with a background in technology research and development, Su Lin did not discuss the commercial value behind "Qingshan Avatrombopag" at the first time, but instead questioned its rationality.

"I don't believe it either. It really sounds too outrageous."

Su Wenping smiled bitterly and shook his head:

"Let's not talk about other things first. Just the screening of compounds and the laboratory data are not something that can be completed by two people, but..."

"I specifically checked the patents they applied for. Both the crystal form and the compound are completely different from the 'Avatrombopag' developed by AkaRx.
I can only say that this guy is a genius!"

"genius?"

Su Lin shook his head jokingly, obviously not believing it at all.

"Well, whether it's genius, luck, or just picked it up somewhere, it doesn't matter. Anyway, this new drug has appeared!"

"Wenping, tell me what you think. Should we buy this drug patent or discuss cooperation?"

Su Wenping is the head of Hengrui's BD trading department.

Hearing this, he nodded without hesitation, and his eyes fell on the clinical data of "Qingshan Avatrombopag Tablets" again, with a hint of amazement still in his eyes!
"Mr. Su, the clinical data of this new drug is really amazing!"

"Most of its data not only reach the effect of AkaRx's 'Avatrombopag', but some clinical effects even slightly exceed it. It is no exaggeration to call it the domestic version of 'Avatrombopag'!"

"At present, our company's star products are mainly oncology drugs. If we can introduce this 'Avatrombopag', it will undoubtedly bring fresh blood to the company's entire product series."

"So, I strongly agree to buy this drug patent. At the very least, we should find a way to negotiate cooperation with them!"

Su Lin nodded.

After a while, he said:
"Well, I'll leave this matter to you. Contact them first and test their willingness to see if they are willing to sell it!"

"Okay, I'll do it myself!"

……

The conversations among Hengrui executives are just the tip of the iceberg for the entire industry.

As the Phase II clinical data of Qingshan Avatrombopag spread in the industry, several other innovative pharmaceutical companies in China also held similar meetings.

All the meetings had only one topic - to make contact and see if they could acquire the patent. Of course, Beifeng Pharmaceuticals also noticed such a big move.

In the office, Ding Jian's face was cold.

Ever since He Youcai was ruthlessly rebuked by Zhang Yang a few days ago, he has been in an extremely gloomy mood.

I originally wanted to see if I could find a breakthrough from Ren Xiaomin, but I didn't expect that before I took any action, Zhang Yang would make the second phase data of "Qingshan Avaqubopa" public.

This announcement obviously disrupted his plans. Now all pharmaceutical companies have their eyes on Qingshan Avatrombopag, and it is almost impossible for him to buy it at a low price!
"Boss, what should we do now?"

"Zhang Yang's attitude towards us was already very bad. If other pharmaceutical companies contact them now, I'm afraid we will have no chance at all!"

The person who spoke was He Youcai. When the news came, he became a little anxious because he knew the inside story.

Ding Jian had a gloomy face and did not answer.

"How about... Boss, let's talk to them again right away?"

"We'll offer a good price this time, and I'll lower my attitude a little... No, I'll go to their house and apologize in person!"

"Apologize? Idiot!"

Ding Jian finally spoke.

"I've told you so many times, don't panic when something happens!"

"Think about it, they were so arrogant when we contacted them a few days ago. Now I don't know how many pharmaceutical companies are contacting them. Do you think they will treat us well?"

"Talking to them now will only hand over the initiative to them, and we will be completely led by them!"

He Youcai suddenly came to his senses when he heard this.

This is indeed the case. When I contacted Zhang Yang a few days ago, both parties were at least on an equal footing. Now the other party has raised the price and is waiting for the right price. If we continue to negotiate, we will be in a passive position!
"Boss, what should we do next?"

"We can't just sit there and watch other pharmaceutical companies contact Zhang Yang and make a deal, right?"

"Of course not!"

Ding Jian fell into deep thought, his brows furrowed. After several minutes, he suddenly whispered:
"What is Zhang Yang's biggest problem now?"

"Insufficient funds!" He Youcai said anxiously.

"Yes."

Ding Jian's eyes gradually became fierce:

"Spread this news and let everyone know that they have run out of funds and have no money to continue the Phase III clinical trial!"

"If this happens, after those old guys find out, no one will be willing to pay a high price to Zhang Yang. I know them very well, none of them is easy to deal with!"

He Youcai was stunned for a moment, and then he was amazed!
Now other pharmaceutical companies don’t know Zhang Yang’s background and are begging him to sell the drug patents to them.

But once these pharmaceutical companies know that Zhang Yang has no money to advance the next clinical trials, the nature of the situation will be completely different!

It went from waiting for a good price to having to sell it off!

The price is way too different!
Once the price expectations differ too much, there will be no agreement!

High!

So high!
Thinking of this, he couldn't help but glance at his boss Ding Jian. Once this move was made, Zhang Yang immediately went from being active to being passive!

But at this time, Ding Jian continued:

"That's not enough!"

“Youcai, don’t we have some connections at the Clinical Trial Review Center?”

"Go move!"

(End of this chapter)